Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tracheal mucous velocity was measured in 13 healthy non-smokers using a radioisotope-labeled aerosol and a multidetector probe during respiratory virus infections. The movement of boluses of tracheal mucous were either absent or reduced in number in five subjects with myxovirus infection (four influenza and one respiratory syncytial virus) within 48 hr of the onset of symptoms and in four subjects 1 wk later. One subject with influenza still had reduced bolus formation 12-16 wk after infection. Frequent coughing was a feature of those subjects with absent tracheal boluses. In contrast, four subjects with rhinovirus infection had normal tracheal mucous velocity at 48 hr after the onset of symptoms (4.1 +/- 1.3 mm/min). Tracheal mucous velocity was also normal (4.6 +/- 1.1 mm/min) in four subjects in whom no specific viral agent could be defined but of respiratory viral infection. During health tracheal mucous velocity was (4.8 +/- 1.6 mm/min) in the eleven subjects who had measurements made. Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.
 ...
PMID:The effects of acute respiratory virus infection upon tracheal mucous transport. 300 87

Between 30,000-40,000 Americans die annually as a result of influenza epidemics. Spread primarily through the respiratory tract, influenza's classic signs and symptoms are the abrupt onset of fever, myalgia, headache, sore throat, malaise, and nonproductive cough. The elderly and patients with underlying medical illnesses may be at risk for secondary complications. Influenza is caused by an RNA myxovirus that exists in types A, B, and C; however, the A and B types are responsible for most human illness. The Centers for Disease Control and Prevention tracks the viruses' regular pathway through the US each year as they emerge first in Alaska and spread through the lower 48 states, peaking in activity during the winter months. Influenza is preventable by vaccination (efficacy 70%, depending on individual immune status) and is recommended for everyone at increased risk of complications from influenza between 6 months and 50 years of age, and universally for those over the age of 50. The composition of the vaccine has been changed for 2000-2001 to include two new type-A strains and one new type-B. Currently four drugs are available for the treatment of influenza. Early diagnosis can help reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. Bacterial infections can have similar symptoms or be complications of influenza and should be suspected and treated appropriately if present.
 ...
PMID:Influenza update 2000. 2176